Growth Ahead of Governance - UK Medical Cannabis in 2026
The data behind the UK's 140,000-patient medical cannabis boom, and the regulators stepping in to check it.
Source: Prohibition Partners, UK Medical Cannabis Market Update 2026, June 2026
From niche to 140,000 patients in two years
The UK medical cannabis market has undergone a structural shift since legalisation. Prohibition Partners estimates more than 140,000 patients will be prescribed medical cannabis in 2026 — up from approximately 100,000 a year earlier.
Almost all access occurs through private-pay online clinics rather than the NHS, which limits prescribing to three narrow indications: rare childhood epilepsy, chemotherapy-induced nausea, and muscle spasticity in multiple sclerosis.
More than 40 private clinics now operate nationally. Just eight platforms account for an estimated 80% of all prescriptions — high concentration in an unregulated access model.
’ Prohibition Partners projection · Source: UK Medical Cannabis Market Update 2026
“This is no longer a niche, fringe market. In the space of two years, the UK has become one of the fastest-growing medical cannabis markets anywhere in the world, and most people have no idea it’s happening on this scale.
Source: Prohibition Partners, UK Medical Cannabis Market Update 2026
Canada now dominates UK supply after 562% surge
Imports doubled in a single year — from 14,992 kg in 2024 to 30,061 kg in 2025 — driven almost entirely by Canadian exports, which rose 562% from 2.58 tonnes to 17.07 tonnes.
Canada now accounts for an estimated 70–80% of all medical cannabis entering the UK, once products routed through Portugal and other countries are included.
Spain, which supplied over half of UK imports as recently as 2023, has seen its share collapse to just 11%. UK domestic production currently covers around 14% of supply — projected to fall to 9% by 2030 as imports grow faster.
Source: Prohibition Partners, UK Medical Cannabis Market Update 2026
Prices falling as supply floods the market
Increased competition between international suppliers has driven prices down across all product types. The average price of medical cannabis flower — the most widely prescribed format — fell from £7.10 to £6.80 per gram over the past year.
Vape product prices fell even more sharply, declining by approximately 25% over the same period. Falling prices improve patient affordability, but compress margins across the supply chain and accelerate market consolidation.
For employers and HR professionals: the cost of private medical cannabis treatment is increasingly within reach of more patients, making workplace policy clarity more important, not less.
A £345m market on course for £935m by 2030
Prohibition Partners places the base-case UK market value at £345 million in 2026, with an upside scenario of £398 million. By 2030, the firm projects the market will grow to approximately £935 million, with the patient population approaching 390,000.
Product availability has expanded at a similar pace to patients. Licensed cannabis-based medicines available in the UK increased from 374 in April 2025 to 818 by March 2026 — more than doubling in under a year as international competition intensified.
Dried flower remains the dominant format, accounting for roughly 80% of available products, though vapes and extracts are growing share.
Source: Prohibition Partners, UK Medical Cannabis Market Update 2026
Regulators circling as private clinics scale unchecked
CQC concerns raised
The Care Quality Commission has raised concerns about oversight, documentation and prescribing practices at some private cannabis clinics. No formal enforcement action has yet been taken.
ACMD review expected
The Advisory Council on the Misuse of Drugs is expected to formally review the sector in 2026 or 2027, which may have implications for prescribing practices, clinic standards, and patient access frameworks.
NHS remains largely closed
The NHS will only advocate medical cannabis in three narrow circumstances: rare severe epilepsy, chemotherapy-induced nausea, and muscle spasticity in MS. Almost all other patients pay privately.
Sources & Citation Guide
All data on this page is drawn directly from the UK Medical Cannabis Market Update 2026 published by Prohibition Partners (June 2026). Additional reporting sourced from Cannabis Health News.
Suggested citation for journalism / HR publications:
“According to the UK Medical Cannabis Market Update 2026 by Prohibition Partners, as reported by Kalu (kalu.health/uk-medical-cannabis-report-2026), [statistic].”